Drug biotransformation study is an integral part of preclinical screening for new drug candidates. This assessment usually involves both in vitro and in vivo models in animal species where the main pharmacokinetics, pharmacodynamics and toxicological profile are investigated. Several in vitro models utilized in studying hepatic drug biotransformation. Such models which range from whole cell system (intact perfused liver, human hepatocytes culture, hepatic and transfected cell lines)to enzymes preparations (liver Microsomes, cytosolic and S9 fraction) are now increasingly applied for quantitative and qualitative assessment in preclinical drug development, post-approval routine checks, identification of metabolic determinant factor etc. A literature survey was done to study reported metabolites and metabolic pathway of pazopanib Ex-vivo protocol for metabolic assessment was developed after collecting the appropriate enzymatic fraction. RHPLC method was developed and validated for quantitation of pazopanib in presence of metabolizing enzymes. Microsomal fraction was isolated from goat liver obtained from slaughterhouse using centrifugation technique. A sample was incubated with pazopanib and also in the presence of microsomal enzyme inducer and inhibitor and sample withdrawn at different time interval were subjected to analysis by the developed HPLC method for detection of possibly formed metabolites. The developed chromatographic method will be a handy tool for assessment of quantitative formation as such metabolites and will help in metabolic stability for pazopanib.